A Study Evaluating APG777 in Atopic Dermatitis - Trial NCT06395948
Access comprehensive clinical trial information for NCT06395948 through Pure Global AI's free database. This Phase 2 trial is sponsored by Apogee Therapeutics, Inc. and is currently Recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 471 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Apogee Therapeutics, Inc.
Timeline & Enrollment
Phase 2
Apr 29, 2024
Jun 01, 2028
Primary Outcome
Part A and B: Percent Change From Baseline in Eczema Area and Severity Index (EASI)
Summary
This is a two-part study that will evaluate the safety and efficacy of APG777 in participants
 with moderate-to-severe Atopic Dermatitis (AD). Part A will evaluate the safety and efficacy
 of one induction dose regimen of APG777 compared to placebo. In addition, two maintenance
 regimens will be evaluated in Part A. Part B will evaluate the benefit-risk of 3 dose
 regimens of APG777 compared to placebo. One maintenance regimen will be evaluated in Part B.
 The study duration for any individual participant will be up to 106 weeks which includes:
 screening, induction, maintenance, and post-treatment follow-up periods. Participants
 randomized in Part A are not permitted to participate in Part B.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06395948
Non-Device Trial